Stock Track | Amylyx Pharmaceuticals Plummets 8.16% Intraday on Wider-Than-Expected Q1 Loss

Stock Track05-08

Amylyx Pharmaceuticals' stock plummeted 8.16% during intraday trading on Thursday, following the release of its first-quarter 2026 financial results.

The biotech firm reported a net loss of $41.3 million, or $0.37 per share, for the quarter, which was wider than both the $35.9 million loss from a year earlier and analyst expectations. The company's results missed consensus estimates for EPS, net income, and operating income, with the higher loss primarily driven by increased research and development expenses related to the clinical development of its investigational drug avexitide for post-bariatric hypoglycemia.

R&D expenses rose to $27.6 million from $22.1 million a year ago, which included $4 million in milestone payments to collaborator Gubra. The company noted that its cash runway is expected to fund operations into 2028, with topline data from the Phase 3 LUCIDITY trial of avexitide anticipated in the third quarter of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1195103077?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-08 00:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1195103077","market":"sg","top_or_hot":-1,"title":"Stock Track | Amylyx Pharmaceuticals Plummets 8.16% Intraday on Wider-Than-Expected Q1 Loss","media":"Stock Track","content":"<p>Amylyx Pharmaceuticals' stock plummeted 8.16% during intraday trading on Thursday, following the release of its first-quarter 2026 financial results.</p><p>The biotech firm reported a net loss of $41.3 million, or $0.37 per share, for the quarter, which was wider than both the $35.9 million loss from a year earlier and analyst expectations. The company's results missed consensus estimates for EPS, net income, and operating income, with the higher loss primarily driven by increased research and development expenses related to the clinical development of its investigational drug avexitide for post-bariatric hypoglycemia.</p><p>R&D expenses rose to $27.6 million from $22.1 million a year ago, which included $4 million in milestone payments to collaborator Gubra. The company noted that its cash runway is expected to fund operations into 2028, with topline data from the Phase 3 LUCIDITY trial of avexitide anticipated in the third quarter of 2026.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Amylyx Pharmaceuticals Plummets 8.16% Intraday on Wider-Than-Expected Q1 Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Amylyx Pharmaceuticals Plummets 8.16% Intraday on Wider-Than-Expected Q1 Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-08 00:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Amylyx Pharmaceuticals' stock plummeted 8.16% during intraday trading on Thursday, following the release of its first-quarter 2026 financial results.</p><p>The biotech firm reported a net loss of $41.3 million, or $0.37 per share, for the quarter, which was wider than both the $35.9 million loss from a year earlier and analyst expectations. The company's results missed consensus estimates for EPS, net income, and operating income, with the higher loss primarily driven by increased research and development expenses related to the clinical development of its investigational drug avexitide for post-bariatric hypoglycemia.</p><p>R&D expenses rose to $27.6 million from $22.1 million a year ago, which included $4 million in milestone payments to collaborator Gubra. The company noted that its cash runway is expected to fund operations into 2028, with topline data from the Phase 3 LUCIDITY trial of avexitide anticipated in the third quarter of 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMLX","symbol_name":"Amylyx Pharmaceuticals","start_time":0,"source_url":"","article_id":"1195103077","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195103077","pubTimestamp":1778171778,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Amylyx Pharmaceuticals' stock plummeted 8.16% during intraday trading on Thursday, following the release of its first-quarter 2026 financial results.The biotech firm reported a net loss of $41.3...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AMLX":"Amylyx Pharmaceuticals"},"translate_title":"个股追踪|Q1亏损超预期Amylyx制药盘中暴跌8.16%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMLX":1},"content_text":"Amylyx Pharmaceuticals' stock plummeted 8.16% during intraday trading on Thursday, following the release of its first-quarter 2026 financial results.The biotech firm reported a net loss of $41.3 million, or $0.37 per share, for the quarter, which was wider than both the $35.9 million loss from a year earlier and analyst expectations. The company's results missed consensus estimates for EPS, net income, and operating income, with the higher loss primarily driven by increased research and development expenses related to the clinical development of its investigational drug avexitide for post-bariatric hypoglycemia.R&D expenses rose to $27.6 million from $22.1 million a year ago, which included $4 million in milestone payments to collaborator Gubra. The company noted that its cash runway is expected to fund operations into 2028, with topline data from the Phase 3 LUCIDITY trial of avexitide anticipated in the third quarter of 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1195103077","isCrawlerRequest":true}